NCT01448720View on ClinicalTrials.gov

Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate

PHASE3CompletedINTERVENTIONAL

Enrollment

142

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions

Schizophrenia

Interventions

DRUG

Paliperidone palmitate

Type=exact number, unit=mg, number=150, 100, 75 mg equivalent (eq), form=suspension for injection, route=intramuscular use. One IM injection of 150 mq on Day 1, 100 mg eq. on Day 8 (+/- 4 days), and 75 mg eq. is recommended on Days 36, 64, and 92.

Trial Locations (12)

Unknown

Porto Alegre

Riberao Preto

São José

São Paulo

Barranquilla

Bogotá

Bucarmanga

Medellín

Acapulco

Guadalajara

México

Monterrey

All Listed Sponsors

lead

Janssen-Cilag Farmaceutica Ltda.

INDUSTRY

NCT01448720 - Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate | Biotech Hunter | Biotech Hunter